Femasys Inc (FEMY) Stock Price & Analysis
Femasys Inc (FEMY) fell 2.11% to USD 3.71 as of July 25, 2026 at 10:04 UTC, according to Nexqual real-time market data.
FEMY last closed at USD 3.79; the session ranged USD 3.59–3.92 on volume of 35,249 shares. Market capitalization is $11.20M, with a 52-week range of USD 2.9–22.2 (NCM). Source: Nexqual, July 25, 2026 at 10:04 UTC.
Key Statistics (as of July 25, 2026 at 10:04 UTC)
| Price | USD 3.71 |
|---|---|
| Change | ▼ 2.11% (down) |
| Previous Close | USD 3.79 |
| Open | USD 3.8 |
| Day Range | USD 3.59 – 3.92 |
| 52-Week Range | USD 2.9 – 22.2 |
| Volume | 35,249 shares |
| Market Cap | $11.20M |
| Exchange | NCM |
Technical Analysis (FEMY)
Nexqual's technical model rates FEMY "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:04 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.02 (neutral) |
| vs SMA50 | Below (USD 5.13) |
| MACD | -0.4 (negative) |
Analyst Ratings (FEMY)
Wall Street analysts rate FEMY "None", with a mean price target of USD 63.33 (range USD 30–130), per Nexqual as of July 25, 2026 at 10:04 UTC.
| Consensus Rating | None |
|---|---|
| Mean Target | USD 63.33 |
| High Target | USD 130 |
| Low Target | USD 30 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (FEMY)
| EPS Estimate | USD -1.4 |
|---|---|
| Revenue Estimate | $730,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.46 vs est -1.8 ▲ beat |
| 2025-12-31 | USD -0.2 vs est -1.8 ▲ beat |
| 2025-09-30 | USD -2 vs est -2.6 ▲ beat |
| 2025-06-30 | USD -3.2 vs est -3.6 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
Financials & Fundamentals (FEMY)
| Total Revenue | $2.38M |
|---|---|
| Revenue Growth (YoY) | +24.50% |
| Gross Margin | +61.56% |
| Operating Margin | -994.03% |
| Profit Margin | +0.00% |
| ROE | -255.96% |
| Debt / Equity | 64.86 |
| Current Ratio | 3.91 |
| Total Cash | $5.39M |
| Total Debt | $4.73M |
| Free Cash Flow | $-11.76M |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
Financial Health Score (FEMY)
Nexqual rates Femasys Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 10:04 UTC.
| Growth | Strong — Revenue +41% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $5M cash vs $5M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Critical — ROE -256%, ROA -68.7% |
Ownership (FEMY)
| Insider Ownership | +9.40% |
|---|---|
| Institutional Ownership | +10.11% |
| Shares Outstanding | 3.02M |
| Float | 2.50M |
| Short % of Float | +6.74% |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
Leadership (FEMY)
Femasys Inc is led by Kathy Lee-Sepsick (age 57), Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 10:04 UTC.
| Founder, President, CEO & Director | Kathy Lee-Sepsick (age 57) |
|---|---|
| Chief Financial Officer | Dov Elefant (age 58) |
| Chief Operating Officer | John Canning (age 51) |
| Chief Technology Officer | Jeremy Alexander Sipos (age 51) |
| Vice President of Counsel & Intellectual Property | Mary An Merchant |
Major Backers & Investors (FEMY)
Notable institutional backers of Femasys Inc include Dauntless Investment Group, LLC , Fidelity, Clear Creek Financial Management, LLC, according to Nexqual as of July 25, 2026 at 10:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dauntless Investment Group, LLC | 9.99% |
| Fidelity | 0.85% |
| Clear Creek Financial Management, LLC | 0.19% |
| EP Wealth Advisors, LLC | 0.17% |
| Xtx Topco Ltd | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.52% |
| Geode Capital | 1.03% |
| BlackRock | 0.52% |
| Northern Trust | 0.2% |
| State Street | 0.13% |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
From Femasys Inc's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- We have raised over $170 million since inception from both institutional and strategic investors, including Medtronic and executives from leading life science companies and our initial public offering, or IPO, in June 2021.   Our Intellectual Property and Production Capabilities   We have designed and developed the proprietary methods utilized in our women's health solutions so that they are protected by patents, know-how, and trade secrets.
- FDA-cleared and approved in Europe, UK, Canada, Israel and New Zealand.   FemBloc ® permanent birth control is a revolutionary first-in-class non-surgical solution, which involves minimally-invasive placement of a patented delivery system for precise delivery of our proprietary synthetic tissue adhesive (blended polymer) into both fallopian tubes simultaneously.
- Blocked fallopian tubes are necessary for successful permanent birth control, and FemChec offers significant advantages over other existing approaches, including use of existing ultrasound.   In June 2023 we received an IDE approval from the FDA to allow us to initiate the first phase of the pivotal trial for the FemBloc system followed by a confirmation test with FemChec (Clinicaltrials.gov NCT05977751).
- We estimate the immediately addressable U.S. market for FemaSeed, FemVue, a companion diagnostic product, and FemSperm, for in-office handling of sperm by the gynecologist, may be over $1 billion.   Execute on our clinical program to achieve FDA approval to advance our FemBloc system for use together with FemChec, our companion diagnostic device for ultrasound confirmation, as the preferred option for permanent birth control for women.
Partnerships
- Genetic testing of the eggs or embryo, also known as preimplantation genetic testing (PGT), is an often optional cost up to $10,000 or more if disorders are tested.
- We believe that we currently have sufficient capacity to meet clinical program demands, product supply and launch requirements for the FemaSeed and FemBloc products, both in the U.S. and in select international countries, and believe that we will be able to scale up our capacity relatively quickly with modest capital investment.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ICU | SeaStar Medical Holding Corpora | USD 3.75 | ▼ 3.6% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| SPRC | SciSparc Ltd. | USD 5.33 | ▲ 10.12% |
| TPST | Tempest Therapeutics, Inc. | USD 0.93 | ▼ 2.64% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:04 UTC. This page is informational and not investment advice.